Pharnext
ISIN: FR0011191287 | Ticker: ALPHA | LEI: 969500KJGF9ZUYXSMJ27
Country: France
Our company
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical needs.
Our drug Candidates
Two drug candidates are currently in clinical development: PXT3003 for the treatment of Charcot-Marie-Tooth disease type 1A and PXT864 for Alzheimer’s disease. Both of our lead assets originated from the Pleotherapy R&D approach.
2007
Served areaWorldwide
Headcount44
Headquarters46 Rue Saint Lazare, 75009 Paris – France
FR0011191287
LEI969500KJGF9ZUYXSMJ27
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.